MyMD Pharmaceuticals : Company Overview

New approaches

to treat autoimmune diseases and combat aging

Chris Chapman, M.D.

President, Director and Chief Medical Officer

April 2023

NASDAQ: MYMD

© 2023 MyMD Pharmaceuticals. All Rights Reserved

Forward-Looking Statement

This presentation may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "may," "plan," "will," "would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMD's ability to, obtain and maintain regulatory approvals for clinical trials of MyMD's pharmaceutical candidates; the timing and results of MyMD's planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD's ability to retain and attract senior management and other key employees; MyMD's ability to quickly and effectively respond to new technological developments; MyMD's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD's proprietary rights; and the impact of the COVID-19 pandemic or similar public health emergencies on MyMD's results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed by MyMD on March 31, 2023 as may be supplemented or amended by the company's quarterly reports on Form 10-Q.Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

2

MyMD | Corporate Overview

April 2023

Targeting large markets

with groundbreaking,

next-generation approaches

The MyMD Opportunity

NEXT-GENERATION APPROACH

Positive Data

MYMD-1® first oral, selective TNF-alpha inhibitor

SUPERA-CBD™ novel, potent synthetic cannabidiol (CBD) analog

PIPELINE WITH BROAD	POSITIONED FOR SUCCESS
POTENTIAL

Two Candidates	The Right Team
Targeting Large Markets	to Execute
•	Inflammatory/Autoimmune	•	High-value IP portfolio
	(RA)	•	Experienced team
•	Sarcopenia/frailty (Aging)	•	Prominent advisors
•	Neurologic (Epilepsy, chronic	•	Reputable collaborations
	pain, anxiety)

4

MyMD | Corporate Overview

April 2023

Pipeline with Broad Potential

DRUG CANDIDATE	INDICATION	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	MARKET
	Sarcopenia (Aging)
MYMD-1®	Rheumatoid Arthritis
Immune Regulator	Hashimoto's Thyroiditis
	Additional Programs
	Epilepsy
Supera-CBD™
Chronic Pain
Synthetic CBD Analog
	Anxiety

5

MyMD | Corporate Overview

April 2023